Hong Kong Stocks Movement | KEYMED BIO-B (02162) Rises Nearly 3%, Self-Developed BCMA×CD3 Bispecific Antibody CM336 Granted FTD Designation by FDA

Stock News

Jan 27

KEYMED BIO-B (02162) rose nearly 3%. As of the time of writing, the stock was up 2.24%, trading at HK$57, with a turnover of HK$19.7112 million. On the news front, according to an announcement on KEYMED BIO-B's official WeChat account, the company and its partner Ouro Medicines Ltd. recently announced that their BCMA×CD3 bispecific antibody, CM336 (OM336), has been granted Fast Track Designation (FTD) by the US FDA for the treatment of Autoimmune Hemolytic Anemia (AIHA) and Immune Thrombocytopenia (ITP). The granting of Fast Track Designation for CM336 in both AIHA and ITP indications highlights the urgent need for innovative treatment options for these diseases and further demonstrates CM336's therapeutic potential in autoimmune disorders. Previously, KEYMED BIO entered into an exclusive license agreement with Ouro Medicines Ltd., granting Ouro Medicines the exclusive rights to research, develop, manufacture, register, and commercialize CM336 globally (excluding Mainland China, Hong Kong, Macau, and Taiwan). CM336 has already received Orphan Drug Designation (ODD) from the FDA for the treatment of both AIHA and ITP.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1197938528"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197938528\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1197938528?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 11:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197938528","market":"nz","top_or_hot":-1,"title":"Hong Kong Stocks Movement | KEYMED BIO-B (02162) Rises Nearly 3%, Self-Developed BCMA×CD3 Bispecific Antibody CM336 Granted FTD Designation by FDA","media":"Stock News","content":"<p>KEYMED BIO-B (02162) rose nearly 3%. As of the time of writing, the stock was up 2.24%, trading at HK$57, with a turnover of HK$19.7112 million.\nOn the news front, according to an announcement on KEYMED BIO-B's official WeChat account, the company and its partner Ouro Medicines Ltd. recently announced that their BCMA×CD3 bispecific antibody, CM336 (OM336), has been granted Fast Track Designation (FTD) by the US FDA for the treatment of Autoimmune Hemolytic Anemia (AIHA) and Immune Thrombocytopenia (ITP).\nThe granting of Fast Track Designation for CM336 in both AIHA and ITP indications highlights the urgent need for innovative treatment options for these diseases and further demonstrates CM336's therapeutic potential in autoimmune disorders.\nPreviously, KEYMED BIO entered into an exclusive license agreement with Ouro Medicines Ltd., granting Ouro Medicines the exclusive rights to research, develop, manufacture, register, and commercialize CM336 globally (excluding Mainland China, Hong Kong, Macau, and Taiwan).\nCM336 has already received Orphan Drug Designation (ODD) from the FDA for the treatment of both AIHA and ITP.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stocks Movement | KEYMED BIO-B (02162) Rises Nearly 3%, Self-Developed BCMA×CD3 Bispecific Antibody CM336 Granted FTD Designation by FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stocks Movement | KEYMED BIO-B (02162) Rises Nearly 3%, Self-Developed BCMA×CD3 Bispecific Antibody CM336 Granted FTD Designation by FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-27 11:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>KEYMED BIO-B (02162) rose nearly 3%. As of the time of writing, the stock was up 2.24%, trading at HK$57, with a turnover of HK$19.7112 million.\nOn the news front, according to an announcement on KEYMED BIO-B's official WeChat account, the company and its partner Ouro Medicines Ltd. recently announced that their BCMA×CD3 bispecific antibody, CM336 (OM336), has been granted Fast Track Designation (FTD) by the US FDA for the treatment of Autoimmune Hemolytic Anemia (AIHA) and Immune Thrombocytopenia (ITP).\nThe granting of Fast Track Designation for CM336 in both AIHA and ITP indications highlights the urgent need for innovative treatment options for these diseases and further demonstrates CM336's therapeutic potential in autoimmune disorders.\nPreviously, KEYMED BIO entered into an exclusive license agreement with Ouro Medicines Ltd., granting Ouro Medicines the exclusive rights to research, develop, manufacture, register, and commercialize CM336 globally (excluding Mainland China, Hong Kong, Macau, and Taiwan).\nCM336 has already received Orphan Drug Designation (ODD) from the FDA for the treatment of both AIHA and ITP.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1197938528","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197938528","pubTimestamp":1769484502,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"KEYMED BIO-B (02162) rose nearly 3%. As of the time of writing, the stock was up 2.24%, trading at HK$57, with a turnover of HK$19.7112 million. On the news front, according to an announcement on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","02162":"康诺亚-B","BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股"},"translate_title":"港股动向|康盟生物-B(02162)涨近3%，自研BCMA × CD3双特异性抗体CM336获FDA授予FTD资格","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"KEYMED BIO-B (02162) rose nearly 3%. As of the time of writing, the stock was up 2.24%, trading at HK$57, with a turnover of HK$19.7112 million.\nOn the news front, according to an announcement on KEYMED BIO-B's official WeChat account, the company and its partner Ouro Medicines Ltd. recently announced that their BCMA×CD3 bispecific antibody, CM336 (OM336), has been granted Fast Track Designation (FTD) by the US FDA for the treatment of Autoimmune Hemolytic Anemia (AIHA) and Immune Thrombocytopenia (ITP).\nThe granting of Fast Track Designation for CM336 in both AIHA and ITP indications highlights the urgent need for innovative treatment options for these diseases and further demonstrates CM336's therapeutic potential in autoimmune disorders.\nPreviously, KEYMED BIO entered into an exclusive license agreement with Ouro Medicines Ltd., granting Ouro Medicines the exclusive rights to research, develop, manufacture, register, and commercialize CM336 globally (excluding Mainland China, Hong Kong, Macau, and Taiwan).\nCM336 has already received Orphan Drug Designation (ODD) from the FDA for the treatment of both AIHA and ITP.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}